Immunotherapy of non-small-cell lung cancer

被引：0

作者：

Reinmuth, Niels ^{[1
]}

Merk, Martina ^{[1
]}

Duell, Thomas ^{[1
]}

机构：

[1] Asklepios Fachklin Munchen Gauting, Abt Thorakale Onkol, Robert Koch Allee 2, D-82131 Gauting, Germany

来源：

ONKOLOGE | 2021年 / 27卷 / 02期

关键词：

Immune checkpoint inhibitors; Treatment planning; Long-term survival; Checkpoint inhibitors; side effects; Drug therapy; combined; CHEMOTHERAPY; NSCLC; PEMBROLIZUMAB; UPDATE; PD-1;

D O I：

10.1007/s00761-020-00885-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In recent years, the discovery of the importance of checkpoint inhibitors has fundamentally changed the treatment of non-small-cell lung cancer (NSCLC). To date, various programmed cell death 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1) checkpoint inhibitors have been approved in stage III or IV NSCLC. Moreover, several treatment options for checkpoint inhibitors with or without combinational chemotherapy may be used for treatment of stage IV disease. In addition, immune modulatory strategies with new combinations, new targets, or used in early stages are being explored. Consequently, we may expect even more treatment options in the near future. This is likely to also require establishment of further decision criteria and continuing education for treating physicians.

引用

页码：179 / 190

页数：12

共 34 条

[1] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Kurata, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

Carpeno, J. de Castro ;

Faivre-Finn, C. ;

Reck, M. ;

Vansteenkiste, J. ;

Spigel, D. R. ;

Wadsworth, C. ;

Melillo, G. ;

Taboada, M. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) :2342-2350

[2] Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study [J].

Barlesi, Fabrice ;

Vansteenkiste, Johan ;

Spigel, David ;

Ishii, Hidenobu ;

Garassino, Marina ;

de Marinis, Filippo ;

Ozguroglu, Mustafa ;

Szczesna, Aleksandra ;

Polychronis, Andreas ;

Uslu, Ruchan ;

Krzakowski, Maciej ;

Lee, Jong-Seok ;

Calabro, Luana ;

Frontera, Osvaldo Aren ;

Ellers-Lenz, Barbara ;

Bajars, Marcis ;

Ruisi, Mary ;

Park, Keunchil .

LANCET ONCOLOGY, 2018, 19 (11) :1468-1479

[3] Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway [J].

Boussiotis, Vassiliki A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (18) :1767-1778

[4] KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50% [J].

Brahmer, J. R. ;

Rodriguez-Abreu, D. ;

Robinson, A. G. ;

Hui, R. ;

Csoszi, T. ;

Fulop, A. ;

Gottfried, M. ;

Peled, N. ;

Tafreshi, A. ;

Cuffe, S. ;

O'Brien, M. ;

Rao, S. ;

Hotta, K. ;

Leal, T. A. ;

Riess, J. W. ;

Jensen, E. ;

Zhao, B. ;

Pietanza, M. C. ;

Reck, M. .

ANNALS OF ONCOLOGY, 2020, 31 :S1181-S1182

[5] Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study [J].

Cappuzzo, Federico ;

Ciuleanu, Tudor ;

Stelmakh, Lilia ;

Cicenas, Saulius ;

Szczesna, Aleksandra ;

Juhasz, Erzsebet ;

Esteban, Emilio ;

Molinier, Olivier ;

Brugger, Wolfram ;

Melezinek, Ivan ;

Klingelschmitt, Gaelle ;

Klughammer, Barbara ;

Giaccone, Giuseppe .

LANCET ONCOLOGY, 2010, 11 (06) :521-529

[6] Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1 [J].

Chen, Daniel S. ;

Irving, Bryan A. ;

Hodi, F. Stephen .

CLINICAL CANCER RESEARCH, 2012, 18 (24) :6580-6587

[7] A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier cancer research network LUN 14-179 [J].

Durm, Greg A. ;

Jabbour, Salma K. ;

Althouse, Sandra K. ;

Liu, Ziyue ;

Sadiq, Ahad A. ;

Zon, Robin T. ;

Jalal, Shadia, I ;

Kloecker, Goetz H. ;

Williamson, Michael J. ;

Reckamp, Karen L. ;

Langdon, Robert M. ;

Kio, Ebenezer A. ;

Gentzler, Ryan D. ;

Adesunloye, Bamidele A. ;

Harb, Wael A. ;

Walling, Radhika, V ;

Titzer, Michael L. ;

Hanna, Nasser H. .

CANCER, 2020, 126 (19) :4353-4361

[8] The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? [J].

Elkrief, A. ;

Derosa, L. ;

Kroemer, G. ;

Zitvogel, L. ;

Routy, B. .

ANNALS OF ONCOLOGY, 2019, 30 (10) :1572-1579

[9] Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial [J].

Faivre-Finn, C. ;

Vicente, D. ;

Kurata, T. ;

Planchard, D. ;

Paz-Ares, L. ;

Vansteenkiste, J. F. ;

Spigel, D. R. ;

Garassino, M. C. ;

Reck, M. ;

Senan, S. ;

Naidoo, J. ;

Rimner, A. ;

Wu, Y-L. ;

Gray, J. E. ;

Ozguroglu, M. ;

Lee, K. H. ;

Newton, M. ;

Wang, L. ;

Thiyagarajah, P. ;

Antonia, S. J. .

ANNALS OF ONCOLOGY, 2020, 31 :S1178-S1179

[10] Neoadjuvant PD-1 Blockade in Resectable Lung Cancer [J].

Forde, P. M. ;

Chaft, J. E. ;

Smith, K. N. ;

Anagnostou, V. ;

Cottrell, T. R. ;

Hellmann, M. D. ;

Zahurak, M. ;

Yang, S. C. ;

Jones, D. R. ;

Broderick, S. ;

Battafarano, R. J. ;

Velez, M. J. ;

Rekhtman, N. ;

Olah, Z. ;

Naidoo, J. ;

Marrone, K. A. ;

Verde, F. ;

Guo, H. ;

Zhang, J. ;

Caushi, J. X. ;

Chan, H. Y. ;

Sidhom, J. -W. ;

Scharpf, R. B. ;

White, J. ;

Gabrielson, E. ;

Wang, H. ;

Rosner, G. L. ;

Rusch, V. ;

Wolchok, J. D. ;

Merghoub, T. ;

Taube, J. M. ;

Velculescu, V. E. ;

Topalian, S. L. ;

Brahmer, J. R. ;

Pardoll, D. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (21) :1976-1986

← 1 2 3 4 →